<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3107">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04455308</url>
  </required_header>
  <id_info>
    <org_study_id>35RC20_8888_ECCES</org_study_id>
    <nct_id>NCT04455308</nct_id>
  </id_info>
  <brief_title>COVID-19 and Chilblains</brief_title>
  <acronym>ECCES</acronym>
  <official_title>Chilblains, COVID-19 and Lockdown: Epidemiologic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chilblains (inflammatory lesion of the feet or hands) have been reported with an unusual&#xD;
      frequency during the confinement period, most commonly in children, teenagers and young&#xD;
      adults. The aim of the ECCES study is to find out whether these manifestations of chilblains&#xD;
      can be linked to the SARS-CoV-2 coronavirus.&#xD;
&#xD;
      For this, an epidemiologic study will compare two types of family (or more precisely people&#xD;
      who were confined together in March-April-May):&#xD;
&#xD;
        -  &quot;case family&quot; in which at least one of the members had chilblains&#xD;
&#xD;
        -  &quot;comparator family&quot; in which none of the members had chilblains Environment (home&#xD;
           lockdown) of the two types of family will be analyzed. Each member of the &quot;family&quot; will&#xD;
           be suggested doing a serological test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Actual">October 19, 2020</completion_date>
  <primary_completion_date type="Actual">October 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of viral exposure in &quot;case family&quot; compared to &quot;comparator family&quot;</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of seropositivity rates in subjects with chilblains and their age-matched controls</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of SARS-CoV-2 seropositivity rates among members of case (subject with chilblains) and control (subject without chilblains) outbreaks</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody avidity and differentiated IgG and IgM assay by subject in the homes</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Chilblains</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Subjects with chilblains</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects without chilblains</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biological sample collection</intervention_name>
    <description>10mL blood sample</description>
    <arm_group_label>Subjects with chilblains</arm_group_label>
    <arm_group_label>Subjects without chilblains</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &quot;case family&quot;&#xD;
&#xD;
          -  at least one of the members with chilblains&#xD;
&#xD;
          -  diagnosis of chilblains (anamnesis and pictures) written informed consent&#xD;
&#xD;
          -  &quot;comparator family&quot;&#xD;
&#xD;
          -  none of the members with chilblains&#xD;
&#xD;
          -  one member matched on age (+/- 1 year) to a patient with chilblains&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Subject legally protected (under judicial protection, guardianship), persons deprived of&#xD;
        liberty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chilblains</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

